Rendering of Lilly's forthcoming manufacturing site in Alzey, Germany (Credit: Eli Lilly)

Lil­ly in­vests $2.5B in new Ger­man site to boost tirzepatide sup­ply, $100M for lo­cal biotechs

Eli Lil­ly is set to build a new $2.5 bil­lion fa­cil­i­ty in Ger­many to in­crease man­u­fac­tur­ing ca­pac­i­ty for its block­buster di­a­betes and obe­si­ty drugs, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.